Clinical trials: Peritoneal Carcinosis
Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma
Paricalcitol Versus Pirfenidone for Improving Surgical Resectability in Patients With Peritoneal Cancer
The goal of this clinical trial is to learn if paricalcitol or pirfenidone can help make tumors removable by surgery in adults with peritoneal cancer who are currently unable to have their tumor removed.
- Conditions
- Peritoneal (Metastatic) Cancer, Peritoneal Carcinoma, Peritoneal Carcinosis, Peritoneal Cancer
- Trial name
- RANDY 1A (NCT07856914)
- Testing
- Paricalcitol, pirfenidone
- Volunteers
- 74 people
- Sponsor
- Patrick Wagner, MD, FACS
Ovarian Cancer With Peritoneal Carcinosis
Extended Versus Short Prehabilitation Programme for Patients With Advanced Ovarian Cancer Undergoing Major Surgery
Standard treatment for advanced ovarian cancer includes a combination of cytotoxic chemotherapy and citorreductive surgery. During neo-adjuvant administration of chemotherapy, many patients experience a decline in their…
- Trial name
- SOPHIE II (NCT07509814)
- Testing
- Extended (Long)-Prehabilitation, Standard (Short)-Prehabilitation
- Where
- 5 sites in Spain
- Volunteers
- 225 people
- Sponsor
- Hospital Clinic of Barcelona
Peritoneal Carcinosis, Peritoneal Metastases
Impact of an Omega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients With Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery
The OMNI study is a clinical trial investigating whether a nutritional supplement with added Omega-3 fatty acids can improve surgical outcomes for patients with peritoneal carcinomatosis.
- Conditions
- Peritoneal Carcinosis, Peritoneal Metastases, HIPEC, Cytoreductive Surgery
- Trial name
- OMNI (NCT07478432)
- Testing
- ONS enriched with Omega-3, Standard ONS
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Catholic University of the Sacred Heart
Peritoneal Carcinosis (PC)
Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan
This is an open, non-randomized, phase I-II, pilot study, which evaluates the combination of optimum cytoreductive surgery and hyperthermic intraoperative peritoneal chemotherapy (HIPEC) with mitomycin C (MMC) and irinotecan.
- Trial name
- NCT01226550
- Testing
- cytoreductive surgery and HIPEC
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Hospices Civils de Lyon
Early Stage Ovarian Tumors, Peritoneal Carcinosis
PONDER: Pelvic Peritonectomy in Early Stage Ovarian Tumors
Early-stage ovarian tumors represent approximately 30% of all newly diagnosed ovarian cancers. Current international guidelines recommend random peritoneal biopsies for surgical staging, but the diagnostic yield of these biopsies…
- Trial name
- PONDER (NCT07271914)
- Testing
- systematic surgical approach to wider peritoneal biopsies according with dissection of retroperitoneal spaces, nerve-sparing approach, Histopathologic Analysis
- Where
- Italy
- Volunteers
- 390 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Cancer, Peritoneal Carcinosis
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.
- Trial name
- BCB (NCT04221464)
- Testing
- biological collection, Tissues collections
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Ovarian Cancer With Peritoneal Carcinosis
Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis
This is a Multicenter prospective diagnostic study.
- Trial name
- CARPEMAN (NCT02493972)
- Testing
- GelPort, laparotomy
- Where
- 5 sites in France
- Volunteers
- 40 people
- Sponsor
- Centre Francois Baclesse
Peritoneal Carcinosis
Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis
Peritoneal carcinosis (PC) corresponds to a locoregional extension into the peritoneum of rare primary peritoneal cancers, or more frequently distant extension of digestive cancers (colorectal or gastric) or gynecological…
- Trial name
- IPOXA (NCT02866903)
- Testing
- intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy
- Where
- 6 sites in France
- Volunteers
- 47 people
- Sponsor
- Hospices Civils de Lyon